Related by context. All words. (Click for frequent words.) 58 Confirmatory 57 AVADO 56 confirmatory clinical 56 riociguat 55 phase IIa 55 BRIM3 55 Phase IIb III 55 Phase Ib clinical 55 phase Ib clinical 55 phase Ib 55 phase IIb 55 Phase III 55 nonclinical studies 54 Phase 1b clinical 54 Phase IIa trial 54 GLP toxicology studies 54 PANVAC VF 54 Phase #b/#a 54 fidaxomicin Phase 3 54 serologic 54 BETAS 54 CLIRS trial 54 multicenter Phase II 54 Phase Ib study 54 preliminary metallurgical testwork 54 Phase Ia 53 dose escalation Phase 53 pivotal bioequivalence 53 ENRICH trial 53 rALLy trial 53 VNP#M 53 phase IIb clinical 53 pelvic ultrasound 53 phase IIa clinical 53 elacytarabine 53 PRIMO CABG 53 thorough QT 53 preclinical efficacy 53 Western blot 53 Phase 1a clinical 53 Aplidin 53 Phase II 53 phase 2a 53 Phase 1a 52 randomized Phase III 52 Dose escalation 52 pharmacokinetic studies 52 Preliminary metallurgical 52 Phase 2a trial 52 pharmacokinetic PK study 52 Phase III clinical 52 randomized controlled clinical 52 Coronary angiography 52 ELISpot 52 randomized Phase IIb 52 ADVANCE PD 52 chest radiographs 52 Phase IIa 52 tolevamer 52 dose escalation clinical 52 CA9 SCAN 52 immunohistochemistry IHC 52 Stedivaze 52 phase IIb trial 52 unblinding 52 CLIRS 52 midstage trials 52 Western Blot 52 Phase 2a 51 Phase IIIb clinical 51 CLIA waiver 51 multicenter randomized controlled 51 MAGE A3 ASCI 51 histopathological 51 TLK# 51 Phase 2b 51 Phase IIB 51 unblind 51 Trofex 51 Phase 2a clinical 51 immunohistochemical 51 pharmacodynamic PD 51 Phase IIa trials 51 phase IIb III 51 pharmacokinetic PK 51 APTIMA HPV 51 BLA filing 51 Phase #b/#a trial 51 randomized blinded 51 GRAVITAS trial 51 Phase IIb 51 NO# [002] 51 neratinib 51 Phase 2b study 51 NSABP B 51 serological tests 51 ganetespib 51 methylation markers 51 AVERROES 51 Phase IIb trials 51 subgroup analyzes 51 Cervista HPV HR 51 scintigraphic 50 trastuzumab emtansine T DM1 50 Phase Ib II 50 confirmatory Phase III 50 Phase IIb trial 50 OvaRex MAb 50 randomized controlled multicenter 50 fosbretabulin 50 multicenter randomized placebo controlled 50 randomized Phase 2b 50 bronchial lavage 50 farletuzumab 50 PIX# trial 50 SYMMETRY trial 50 CHAMPION PCI 50 Thorough QT 50 nested PCR 50 preclinical pharmacokinetic 50 PRESEPT 50 randomized multicentre 50 PCR assay 50 K ras mutations 50 PFO migraine 50 randomized multicenter trial 50 heap leach amenability 50 canakinumab 50 Phase 1b 50 alvespimycin 50 ruxolitinib 50 randomized Phase 50 T SPOT.TB 50 registrational 50 Cologuard 50 ToGA 50 HGS ETR1 50 ongoing Phase 1b 50 dose escalation phase 50 urine cytology 50 ADAGIO study 50 CCR5 antagonist 50 Vitaxin 50 Azedra 50 mineralogical studies 50 trastuzumab DM1 T DM1 50 VITAL Trial 50 Septin9 50 EDEMA4 50 EDEMA3 trial 50 genotypic resistance 49 EOquin 49 Phase IIb clinical trials 49 BioNumerik 49 ILLUMINATE 49 ENDEAVOR III 49 ColonSentry ™ 49 IMA# 49 Phase Ib 49 pivotal Phase III 49 ACCEDE 49 STRIDE PD 49 Onrigin 49 phase IIIb 49 Bezielle 49 Urocidin 49 MEND CABG 49 multicentre randomized 49 OvaRex R 49 SAR# [004] 49 PROPEL trial 49 intestinal biopsy 49 COMFORT II 49 Tarceva TM 49 multicenter phase 49 rBChE 49 unblinded 49 Phase III psoriasis 49 CCR5 inhibitor 49 Phase #/#a 49 P2V TM 49 darbepoetin alpha 49 Phase #/#a clinical 49 Phase IIa clinical 49 flotation testwork 49 placebo controlled Phase 49 AttoSense 49 caustic fusion diamond 49 IIa trial 49 balsalazide tablet 49 vitro dissolution 49 blinded randomized placebo controlled 49 iroxanadine 49 OncoVex 49 ELISA assay 49 preclinical toxicology 49 solithromycin 49 Phase III trials 49 pharmacodynamic effects 49 #D#C# 49 anti JCV antibody 49 registrational Phase 49 OncoVEX GM CSF 49 Solorel 49 Prosaptide 49 placebo controlled clinical 49 Phase IIIb study 49 TMC# [002] 49 liver biopsy 49 assessing T DM1 49 PRIMO CABG2 49 registrational trial 49 skin sterol 49 controlled multicenter Phase 49 pharmacokinetics PK 49 galiximab 49 Phase 1b trial 49 Oncotype DX colon cancer 49 molecular biomarker 49 Phase #b/#a clinical 49 geochemical analyzes 49 serological 48 quantitative PCR qPCR 48 tramiprosate Alzhemed TM 48 randomized clinical 48 PLCO 48 Prodarsan ® 48 HCV antibody 48 GALNS 48 dose cohort 48 confirmatory testing 48 FDG-PET/CT 48 masked placebo controlled 48 florbetaben 48 multicenter Phase 48 Premarket Approval 48 Kynapid 48 nab paclitaxel 48 GAP #B# 48 SNT MC# 48 Cloretazine 48 BrachySil TM 48 Fibrillex 48 immunohistochemical analysis 48 Oglemilast 48 ColorectAlert TM 48 elotuzumab 48 Exherin TM 48 histologic diagnosis 48 Cloretazine ® 48 hydroxy vitamin D 48 Vectibix panitumumab 48 Phase IIb clinical 48 assay 48 OvaRex ® MAb 48 HGS ETR2 48 genotoxicity 48 surrogate markers 48 PROCHYMAL 48 PITX2 48 ABSORB trial 48 refractory CLL 48 dose escalation trial 48 blinded randomized 48 crizotinib PF # 48 ixabepilone 48 tesmilifene 48 COLD PCR 48 QTinno TM 48 IIa trials 48 Phase III VISTA 48 DEB# 48 randomized trials 48 multicenter Phase III 48 triphendiol 48 UPLYSO 48 Phase III randomized controlled 48 bosutinib 48 confirmatory tests 48 DermaVir Patch 48 OVATURE 48 Phase 2b trial 48 D dimer 48 PLX cells 48 miRview TM mets 48 APTIMA HPV assay 48 co receptor tropism 48 pharmacokinetic pharmacodynamic 48 vitro experiments 48 PERSEUS 48 receptor tyrosine kinase inhibitor 48 viral kinetic 48 putative biomarkers 48 PS# DARA 48 assays 48 toxicological studies 48 rilonacept 48 ADMIRE HF 48 lung biopsy 48 tuberculin test 48 CELVAPAN H#N# 48 cangrelor 48 AMD# [003] 48 ENDEAVOR IV 48 randomized multicenter Phase III 48 BLOOM DM 48 maribavir 48 rALLy 48 TMC# C# 48 SUCCEED trial 48 BRAF V#E mutation 48 VTEM airborne surveys 48 oral ridaforolimus 48 double blinded randomized 48 immunomagnetic separation 48 perfusion MRI 48 selenium supplementation 48 PEP# [003] 48 BRIM2 48 orBec 48 ELACYT 48 MIRCERA 48 eTag assays 48 LUMINATE 48 mg/m2 cohort 48 EDEMA3 48 PS# [001] 47 PROSTVAC ® 47 XRF analysis 47 StemEx 47 preclinically 47 d dimer 47 Phase Ib clinical trials 47 BLA submission 47 metaanalysis 47 TELCYTA 47 preclinical pharmacology 47 PSMA ADC 47 Phase 2a clinical trials 47 CUSTOM III 47 immunoblotting 47 NADiA ProsVue 47 Phase 2b clinical 47 omega interferon 47 prospective randomized controlled 47 PFGE 47 EchoCRT 47 talabostat 47 placebo controlled Phase III 47 cediranib 47 TOLAMBA 47 LungExpress Dx TM 47 Confirmatory testing 47 Neuvenge 47 Tyrima 47 RRMS patients 47 lintuzumab 47 initiate Phase 1b 47 endometrial biopsy 47 Oncotype DX Recurrence Score 47 EUS FNA 47 immunohistochemistry 47 Phase III confirmatory 47 immunochemical 47 Xpert MRSA 47 miRview squamous 47 Confirmatory tests 47 fidaxomicin Phase 47 YONDELIS 47 OLpur TM H2H 47 Phase IIIb 47 CLL8 47 Telatinib 47 hereditary deficiency 47 placebo controlled randomized 47 Tesmilifene 47 MERLIN TIMI 47 sNDA submission 47 Omnitarg 47 Multiple Ascending Dose 47 Phase Ib IIa clinical 47 satraplatin Phase 47 clinical pharmacology studies 47 midstage studies 47 CAMMS# 47 serologic testing 47 DASISION 47 Tovaxin Phase IIb 47 serologic tests 47 IIb clinical trial 47 HCV RESPOND 2 47 Phase III pivotal 47 eprotirome 47 midstage clinical 47 leachability 47 IND Investigational New 47 randomized clinical trials 47 prospective multicentre 47 ASCEND HF 47 histopathologic 47 clinical trial 47 Ceflatonin 47 Dacogen injection 47 olaparib 47 SEPET TM 47 INCB# [001] 47 Rosetta Genomics microRNA 47 NEO3 47 Bayesian statistical 47 dacetuzumab 47 IMPACT DCM 47 quantitative RT PCR 47 oral rivaroxaban 47 tumor biopsies 47 ATL# [001] 47 HPTN 47 AZILECT ® 47 APEX PD 47 inhaled AAT 47 Humac Laboratories 47 geophysical interpretations 47 Phase lll 47 XL# SAR# 47 D Dimer 47 AZILECT R 47 double blinded placebo 47 Phase 47 Cloretazine R VNP#M 47 multicenter placebo controlled 47 PreGen Plus 47 enzastaurin 47 IND submission 47 AppyScore 47 methylation biomarkers 47 Phase IIa clinical trials 47 samalizumab 47 PROSTVAC TM 47 bortezomib Velcade 47 pathologic examination 47 OHR/AVR# 47 Phase IIA 47 Solorel TM 47 Panzem R NCD 47 Aclidinium 47 clinical trials 47 Rhucin ® 47 microdiamond 47 urodynamic 47 PEARL SC 47 ARIKACE ™ 47 cannabinor 47 TG MV 46 nonrandomized 46 PDE4 inhibitor 46 Recombinant EPO 46 figitumumab 46 JAK inhibitor 46 European Sepsis Trial 46 mTOR inhibition 46 bardoxolone 46 Immunohistochemical 46 stool specimens 46 Hedgehog inhibitor 46 Telintra 46 metallurgical testwork 46 KRAS status 46 arbaclofen 46 UroVysion 46 ataluren 46 multiple ascending dose 46 ONCONASE R 46 vemurafenib 46 CEQ# 46 ANCHOR trial 46 prognostic biomarker 46 PD LID 46 lomitapide 46 multicenter clinical 46 BN# [004] 46 RIGScan CR 46 Phase III HEAT 46 ZACTIMA 46 Illumina GoldenGate 46 HCV SPRINT 46 microbiologic 46 Xcellerated T Cells 46 Phase 2b kidney transplant 46 OraQuick ® 46 BNC# 46 ELISPOT assay 46 ACCLAIM II 46 enoximone 46 qualitative serum 46 Metallurgical testwork 46 Flow cytometry 46 nasopharyngeal swabs 46 cell lysate 46 AMMTEC 46 SPIRIT FIRST 46 CRD5 46 Anturol TM 46 randomized placebo controlled 46 Gram stain 46 CA4P 46 huC# DM4 46 trastuzumab DM1 46 enzymatic assay 46 mertansine 46 GVAX AML 46 alogliptin 46 trodusquemine 46 GetGoal Phase III 46 Arsenic trioxide 46 severe hypercholesterolemia 46 placebo controlled clinical trials 46 Phase III randomized 46 OvaDx 46 GVAX 46 Kahalalide F 46 Asentar 46 virological response 46 dosing cohort 46 Serological 46 TBC# 46 velafermin 46 HGS# 46 caustic fusion 46 MAA submission 46 ganaxolone 46 HuMax CD4 46 phase IIb study 46 ongoing Phase IIIb 46 Subgroup analyzes 46 randomized controlled 46 LB# [003] 46 iniparib 46 PRECISE trial 46 geochemical assay 46 predictive biomarker 46 Cervista 46 miRview ™ squamous 46 adjuvant colon cancer 46 Randomized clinical trials 46 IDI MRSA 46 randomized controlled Phase 46 romidepsin 46 immunoblot 46 PEG IFN 46 guaiac 46 Ereska 46 Virulizin R 46 QTinno ™ 46 proteomic biomarkers 46 Geochemical analyzes 46 torezolid phosphate 46 invasive lobular carcinoma 46 EMPOWER ™ 46 Multimeric 46 CARE HF 46 lenalidomide dexamethasone 46 Tavocept 46 fFN 46 pradefovir 46 vidofludimus 46 MADIT II 46 conventional cytology 46 QTinno 46 Removab 46 creatinine levels 46 vitro molecular diagnostic 46 FDG PET scans 46 single ascending dose 46 confirmatory Phase 46 CoFactor 46 Pharmacokinetic 46 Phase III clinical trials 46 serological testing 46 BrachySil 46 IND enabling 46 Dyloject TM 46 CALGB # [002] 46 Mantoux test 46 Phase Ib IIa 46 Serologic 46 Phase 1b clinical trials 46 Traficet EN 46 hSBA 46 BR.# 46 Curaxin CBLC# 46 APEX AMI trial 46 budesonide foam 46 efficacy endpoint 46 PrevOnco 46 favorable pharmacokinetic profile 46 MDS AML 46 element ICP MS 46 sporicidal product 46 semiquantitative 46 miRview mets 46 CVac 46 GSK# [001] 46 TMPRSS2 ERG fusion 46 NCT# ClinicalTrials.gov 46 ConclusionThis 46 EFAPROXYN 46 IGRAs 46 recurrent glioma 46 EXPLORE Xa 46 proteomic analysis 46 Ozarelix 46 hc2 46 PCA3 assay 46 immunofluorescent 46 polygraphic test 46 humanised monoclonal antibody 46 PGxPredict 46 multicenter clinical trials 46 Randomized Phase 46 Reverset 46 hepatitis B vaccine Heplisav 46 Immunohistochemical staining 46 AeroLEF TM 46 Committee IDMC 46 selective androgen receptor modulator 46 Annexin V 46 HSADL Bhopal 46 microdosing studies 46 IIa clinical trial 45 ChronVac C ® 45 BEZ# 45 pivotal Phase 45 prostate biopsy 45 AQ4N 45 FOLOTYN ® 45 Phase IIa proof 45 NMP# 45 PROactive study 45 buffy coat 45 GAMMAGARD 45 dosing cohorts 45 ImmuKnow 45 ROCKET AF 45 eosinophilic asthma 45 granted Ortec 45 retaspimycin 45 APTIVUS 45 Enzastaurin 45 MultiGEN 45 genotyping assay 45 REVIVE TA 45 OMP #M# 45 Linjeta TM 45 Liraglutide Effect 45 TroVax ® 45 designated HVTN 45 MGd 45 accredited laboratory 45 initiate Phase 2b 45 MEK inhibitor RDEA# 45 mTOR inhibitors 45 KIACTA ™ 45 iii GTx 45 dirucotide 45 MOZOBIL 45 randomized multicenter 45 Prefeasibility 45 modified REGENESIS Phase IIb 45 HBsAg 45 gemcitabine Gemzar ® 45 treatment naive genotype 45 Augment Injectable 45 ELISPOT 45 pomalidomide 45 Testwork 45 APPRAISE 45 ProCord 45 endoscopic gastric ulcers 45 tremelimumab 45 bioequivalence studies 45 chest radiography 45 microdiamonds 45 Plicera 45 StemEx R 45 pharmacodynamic 45 immunochemical fecal occult 45 pharmacodynamic markers 45 eliglustat tartrate 45 KRAS mutation status 45 Amdel 45 CR# vcMMAE 45 DSMB recommended 45 LibiGel Phase III 45 Sensitivity analyzes 45 AERAS-#/Crucell Ad# 45 antinuclear antibody 45 Phase III placebo controlled 45 maximally tolerated dose 45 abnormal cytology 45 PD2i ® 45 Ambrisentan 45 Lymph node 45 Randomized Phase II 45 reslizumab 45 causal inference 45 sunitinib malate 45 lumiliximab 45 PENNVAX B 45 Mipomersen 45 NEUMUNE 45 LEP ETU 45 Fibrillex TM 45 OvPlex 45 cobas HPV Test 45 urine dipstick 45 OLYMPIA registry 45 dose escalation study 45 SPARLON 45 petrographic 45 Omigard 45 Pre RELAX AHF 45 mineralogical analysis 45 APEX AMI 45 AIR CF1 45 infill sampling 45 prion infection 45 Oncotype 45 SCENESSE ® 45 Pivotal Phase III 45 renal biopsy 45 presymptomatic 45 midstage clinical trials 45 active comparator 45 rindopepimut 45 DEXA scans 45 geochemical geophysical 45 Vilazodone 45 orally dosed 45 pediatric malignancies 45 NEBIDO 45 resultsof 45 Torisel 45 TBDx 45 placebo controlled 45 cMET 45 stated Michelle Berrey 45 overlapping toxicities 45 Onalta ™ 45 VEGF inhibitors 45 nonrandomized studies 45 DSMB 45 ProFlu + 45 antimicrobial susceptibility testing 45 multicentre 45 BAL# [002] 45 oral prodrug 45 virological 45 PSN# [002] 45 quantitative PCR 45 IMGN# 45 downhole geophysical 45 Corus CAD 45 proteasome inhibitor 45 Vaxfectin TM formulated 45 Pharmacokinetic PK 45 cervical cytology 45 assay ELISA 45 recombinant PSMA vaccine 45 Phase IIB clinical 45 Viramidine 45 ZYBRESTAT fosbretabulin 45 Saforis 45 COU AA 45 A. phagocytophilum 45 RSD# 45 AEG# 45 Sym# 45 prospective randomized placebo 45 drill hole RMZ# 45 Huntexil 45 PREGNANT Study 45 commercially producible 45 oral picoplatin 45 miRview ™ mets 45 obatoclax 45 GV# [001] 45 Virulizin ® 45 ALK inhibitors 45 QLT# 45 IP geophysical surveys 45 prospective multicenter 45 EOquin TM 45 estrogen receptor ER 45 BREVAGen ™ 45 induced sputum 45 biostatistical analysis 45 postexposure prophylaxis 45 element ICP analysis 45 NOX E# 45 Initiate Phase 45 bio equivalence 45 BCX# 45 ResponseDX Colon TM 45 Mothae 45 LUVENIQ 45 TheraCIM 45 coronary arteriography 45 PCI ExTRACT TIMI 45 Vicinium TM 44 axitinib 44 velaglucerase alfa 44 multicenter multinational 44 alvimopan 44 oral methylnaltrexone 44 sDNA 44 omacetaxine mepesuccinate 44 prospective multicenter randomized 44 Boldenone steroid 44 human microdosing 44 RSD# oral 44 PROGENSA PCA3 assay 44 AzaSite Plus 44 sample 44 vitro diagnostic multivariate 44 statistical significance 44 evidential breath 44 AspirinWorks test 44 MIST II 44 S. maltophilia 44 PRESEPT study 44 GRN# 44 NVA# 44 AlloMap 44 ELISA 44 RSR# 44 meta analysis pooling 44 preclinical studies 44 NVLAP accreditation 44 Randomized controlled 44 HuMax EGFr 44 Meta analyzes 44 Allovectin 7 ® 44 Histopathological 44 Allovectin 7 44 huN# DM1 44 EndoTAG TM -1 44 talactoferrin 44 mutagenicity 44 Bulk sampling 44 Prodarsan 44 ABCSG 44 Clinicaltrials.gov 44 tanespimycin 44 Vaxfectin R adjuvant 44 MyVax personalized immunotherapy 44 RAB drilling 44 Amoxicillin PULSYS Phase III 44 NIV Pune 44 Diamyd r vaccine 44 CRMD# 44 Capesaris 44 Orphan Drug status 44 IP Resistivity survey 44 FDA Investigational Device 44 dexanabinol 44 Histological 44 Epi proColon 44 velafermin belinostat 44 glufosfamide 44 hemagglutination inhibition HAI 44 tubulin inhibitor 44 lavage fluid 44 CINQUIL 44 celgosivir 44 subcutaneous PRO 44 p# antigen 44 COSIRA trial 44 pharmacokinetic 44 urocortin 2 44 histone deacetylase HDAC inhibitor 44 multicenter randomized Phase 44 MVA MUC1 IL2 44 prognostic indicators 44 TQT studies 44 clinically meaningful differences 44 Pharmacodynamic 44 IMPROVE HF 44 preconcentration 44 oral glucose tolerance 44 squamous intraepithelial lesions 44 BHEM surveys 44 PLCO trial 44 reach statistical significance 44 confirmatory Phase 3 44 GLP toxicology 44 PCV1 44 spiral computed tomography 44 ascending dose 44 tissue biopsies 44 Sapacitabine 44 sestamibi 44 cancer neuroendocrine tumor 44 multicenter randomized clinical 44 oral PrEP 44 Darinaparsin 44 Allovectin 7 R 44 R# #mg BID 44 arsenic trioxide ATO 44 refractory acute myeloid 44 intraobserver 44 molecular diagnostic assay 44 electrospray ionisation 44 OraQuick HIV 44 adipiplon 44 Prostate AdenoCarcinoma Treatment 44 genomic profiling 44 preclinical 44 Phase III Pivotal 44 validation 44 BRAF inhibitor 44 AmpliChip 44 Tawke # 44 Gattex 44 Onconase 44 FORTIS M trial 44 baminercept 44 controlled multicenter 44 HPV genotyping 44 Trovax 44 Verigene System 44 bepotastine besilate nasal spray 44 REGEN trial 44 budesonide MMX Phase III 44 IMPACT IMmunotherapy 44 solanezumab 44 NAbs 44 TLR antagonists 44 Phase 2b clinical trials 44 PDX pralatrexate 44 nucleic acid amplification 44 ultrasound elastography 44 Clevudine 44 Subgroup analysis 44 HyQ 44 rRT PCR 44 GRNVAC1 44 Dr. Gabriel Lasala 44 Hormone receptor 44 Fast Track designations 44 TransMID 44 NuroPro PD 44 maturation inhibitor 44 varespladib 44 deforolimus 44 prospective randomized 44 Phenoptin 44 LungExpress Dx 44 MAXY alpha 44 Zoraxel 44 specified secondary endpoints 44 DNA methylation markers 44 CAPACITY trials 44 tolerated dose MTD 44 cytological 44 ponatinib 44 sonographic diagnosis 44 p# inhibitor 44 pralatrexate 44 ExTRACT TIMI 44 multicenter prospective 44 Ophena TM 44 RE LY ® 44 retrospective cohort 44 PMA submission 44 variography 44 PREOS 44 e2 Collector 44 transcriptomic 44 IMC A# 44 DNAWitness Mito 44 antiangiogenic agents 44 ImmuKnow R 44 Phase IIb kidney transplant 44 NP2 Enkephalin 44 Phase #/#a trial 44 cilengitide 44 Bresalier 44 ONTARGET 44 methodological limitations 44 antibody MAb 44 Trastuzumab DM1 44 PRT# 44 Troxatyl 44 Fx #A 44 LE DT 44 afamelanotide 44 HuMax CD# 44 valopicitabine 44 SIMPADICO 44 RQ PCR